Laman UtamaSBHMY • OTCMKTS
add
Sino Biopharmaceutical Unsponsored Caymand Islands ADR
Tutup sebelumnya
$9.05
Julat tahun
$6.69 - $9.65
Permodalan pasaran
61.24B HKD
Bilangan Purata
50.00
Dalam berita
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
(CNY) | Jun 2024info | Perubahan T/T |
---|---|---|
Hasil | 7.94B | 11.14% |
Perbelanjaan pengendalian | 4.78B | 10.58% |
Pendapatan bersih | 1.51B | 139.69% |
Margin untung bersih | 19.01 | 115.78% |
Pendapatan bagi setiap syer | — | — |
EBITDA | 1.98B | 8.88% |
Kadar cukai berkesan | 16.99% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
(CNY) | Jun 2024info | Perubahan T/T |
---|---|---|
Pelaburan tunai dan jangka pendek | 13.18B | -15.93% |
Jumlah aset | 66.70B | 1.62% |
Jumlah liabiliti | 24.58B | -15.76% |
Jumlah ekuiti | 42.12B | — |
Syer tertunggak | 18.21B | — |
Harga kepada buku | 5.03 | — |
Pulangan pada aset | 6.50% | — |
Pulangan pada modal | 8.37% | — |
Aliran Tunai
Perubahan bersih dalam tunai
(CNY) | Jun 2024info | Perubahan T/T |
---|---|---|
Pendapatan bersih | 1.51B | 139.69% |
Tunai daripada operasi | 1.54B | 15.25% |
Tunai daripada pelaburan | -1.02B | 49.91% |
Tunai daripada pembiayaan | -2.05B | -1.42% |
Perubahan bersih dalam tunai | -1.52B | 43.37% |
Aliran tunai bebas | 1.09B | 36.59% |
Perihal
Sino Biopharmaceutical Limited, shortly Sino Biopharm, is a civilian-run enterprise principally engaged in the medicine products business in Mainland China.
Being a member of Charoen Pokphand Group and headquartered in Hong Kong and Beijing, Sino Biopharm is engaged in researching, developing, producing, and selling biopharmaceutical products for the medical treatment of ophthalmia, as well as modernized Chinese medicine and chemical medicine for the treatment of hepatitis through its subsidiaries.
Sino Biopharm is also involved in other minor businesses through its subsidiaries, such as properties, health food, optical glass, optical and auditory products. Wikipedia
CEO
Diasaskan
2000
Tapak web
Pekerja
24,437